Update: Jasper Therapeutics Q3 Adj. EPS $(1.05) Beats $(3.00) Estimate, Sales $8.000M Beat $3.000M Estimate

Benzinga · 2d ago
Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(1.05) per share which beat the analyst consensus estimate of $(3.00) by 65 percent. This is a 96.73 percent increase over losses of $(32.08) per share from the same period last year. The company reported quarterly sales of $8.000 million which beat the analyst consensus estimate of $3.000 million by 166.67 percent.